In settings with a high proportion of non-facility deliveries, provision of misoprostol to pregnant women for self-use in home births has the potential to expand access to uterus-contracting medicines to prevent PPH. A pilot study – the MamaMiso study - implemented at the community level in Uganda examined the safety and feasibility of this model of care.

This one-page document summarizes the study findings which show that misoprostol distributed antenatally for self-administration can be appropriately taken by women delivering at home. For a more in depth understanding of the study, you can read: The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in rural Uganda, Weeks et al. BMC Pregnancy and Childbirth 2015.

Published:
Jun. 2016
Type:
Research Summary
Topic:
Postpartum Hemorrhage
Authors:
Gynuity Health Projects

PDF

Not all resources are available in all formats. Select language to check availability.